In one of the villages reached by boat, I met Zainul Abedin as he mourned his wife, Jahan Aara, 20, who had died in childbirth, along with their baby. It was her first pregnancy, and she got no medical help.

“Maybe she would have died even in a hospital, but at least she would have had a chance,” Zainul Abedin said. “This way she didn’t even have a chance.”
- Nicholas Kristof, I Saw a Genocide in Slow Motion, NYT, MARCH 2, 2018

A year after she began taking the drug, Ms. Patterson, 49, credits it with nearly vanquishing her pain, enabling her to return to work part time for a hospital.

But her family and her husband’s union, which covers the drug’s cost, have been shocked by the mounting bills for the treatments for her and two of her children, who have the same genetic disease. In 2018, the union faced a potential $6 million annual bill for the Patterson household, casting doubt over the future of the labor group’s generous drug coverage and the family’s health. ...
As more and more families are beseeching drug companies and insurers to pay for this novel class of treatments, both big and small employers are getting hit with higher drug bills. It may be for a worker’s child with hemophilia whose treatments can cost over $1 million or for an employee receiving immunotherapy for lung cancer. But not every union or corporate employer has an adequate cushion to absorb these prescription bills. ...
Because Strensiq needs to be taken indefinitely by patients who need it, Ms. Jasperson estimated that the Pattersons’ total drug coverage could cost the union $60 million.
- Katie Thomas and Reed Abelson, The $6 Million Drug Claim, NYT, Aug. 25, 2019

Show php error messages